IRIS

The present invention relates to a combination therapy for treating infections caused by Mycobacterium abscessus and other microbial pathogens in subjects with cystic fibrosis comprising the sequential, simultaneous or separate administration of pyridine-2-thiol 1-oxides or their salts and cystic fibrosis transmembrane conductance regulator (CFTR) modulators.

A pharmaceutical combination for the treatment of lung infections in subjects with cystic fibrosis

Pasca MR;
2024-01-01

Abstract

The present invention relates to a combination therapy for treating infections caused by Mycobacterium abscessus and other microbial pathogens in subjects with cystic fibrosis comprising the sequential, simultaneous or separate administration of pyridine-2-thiol 1-oxides or their salts and cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
2024
10-apr-2024
Microbiology covers the biology and biochemistry of microorganisms, bacterial, viral, and parasitic, as well as the medical implications and treatments of the subset of these organisms known to cause disease in humans and/or animals. Biotechnology applications of microorganisms for basic science or clinical use are also covered. Resources that emphasize immune response to pathogens and its modulation by clinical intervention are excluded and are covered in the Immunology category.
P2458IT
UNIPV, FFC, ARAID, UNIZAR
STAMPA
Inglese
Nazionale
sì
6 Brevetti::6.1 Brevetto
none
Pasca, Mr; Ramon-Garcia, S; Munoz-Munoz, L; Makarov, V.
info:eu-repo/semantics/patent
285
4
6.1 Brevetto
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1495056
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact